Value Research Stocks

Cipla Ltd.

Add to My Investments

Healthcare | Drugs & Pharma

we think vacations are for wimps

37 Stocks to buy right now

Join now and be among the first to discover Stock Ideas

Get the Stocks!

Please wait...

Please wait...

Please wait...

Please wait...

Please wait...

Please wait...

Please wait...

About The Company

Business: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Incorporated: 1935

Chairman: Y K Hamied

Managing Director: Umang Vohra

Group: Cipla

Listing: NSE: CIPLA, BSE: 500087

Headquarters: Mumbai, Maharashtra

Website: www.cipla.com

Key Facts

Market cap: R 38,711.02 Cr

Revenue (TTM): R 16,796.32 Cr

Earnings (TTM): R 1,647.89 Cr

Cash: R 2,744.60 Cr

Total Debt: R 4,316.23 Cr

Promoters' ownership: 36.68%

Liquidity: High

52 Week range: R 389.55 - 586.00

Face value: R2.00

Shares outstanding: 80,62,27,596

Stock Performance

Trailing
Annual

Time Period	Cipla	S&P BSE Sensex	S&P BSE Healthcare
YTD	0.41	0.67	4.31
1 month	3.09	-0.37	4.56
3 months	8.11	5.68	10.87
1 Year	-5.71	14.05	1.49
3 Years	-5.97	15.38	-1.91
5 Years	-6.21	7.60	-1.53
10 Years	3.43	9.04	10.73

As on 20-Jan-2020

Year	Cipla	S&P BSE Sensex	S&P BSE Healthcare
2019	-8.57	14.38	-3.55
2018	-14.55	5.87	-5.89
2017	6.98	27.91	0.49
2016	-13.21	1.95	-12.88
2015	3.40	-5.03	15.06
2014	55.92	29.89	47.43
2013	-3.99	8.98	22.55

Annual Report (FY18)

Review & Analysis

Fall of Pharma
Mohammed Ekramul Haque . 13-Oct-2016
Challenge the equity-return assumption
Aarati Krishnan . 28-Jul-2016
FIIs Vs DIIs: Different strokes
Kumar Shankar Roy . 20-May-2016
The quest for value
Mohammed Ekramul Haque . 20-Oct-2015
Gaining on healthy demand
Mohammed Ekramul Haque and Vikas Vardhan . 09-Sep-2015

News & Announcements

Closure Of USFDA Inspection At Patalganga Manufacturing Facility
20-Jan-2020
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
17-Jan-2020
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011
17-Jan-2020
Statement Of Investor Complaints For The Quarter Ended December 2019 (Revised)
17-Jan-2020
Statement Of Investor Complaints For The Quarter Ended December 2019
17-Jan-2020